Corina Oprea

1.1k total citations
33 papers, 670 citations indexed

About

Corina Oprea is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Corina Oprea has authored 33 papers receiving a total of 670 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 9 papers in Hematology and 7 papers in Molecular Biology. Recurrent topics in Corina Oprea's work include Cancer Treatment and Pharmacology (11 papers), Multiple Myeloma Research and Treatments (9 papers) and Lymphoma Diagnosis and Treatment (6 papers). Corina Oprea is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Multiple Myeloma Research and Treatments (9 papers) and Lymphoma Diagnosis and Treatment (6 papers). Corina Oprea collaborates with scholars based in France, Italy and United States. Corina Oprea's co-authors include Bruno Lioure, P. Dufour, J. Waller, Ermanno Candolfi, Raoul Herbrecht, Valérie Letscher‐Bru, Patrick Lutz, Shanti Natarajan‐Amé, Jean‐Pierre Bergerat and Elias Jabbour and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Corina Oprea

32 papers receiving 651 citations

Peers

Countries citing papers authored by Corina Oprea

Since Specialization

Citations

This map shows the geographic impact of Corina Oprea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Corina Oprea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Corina Oprea more than expected).

Fields of papers citing papers by Corina Oprea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Corina Oprea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Corina Oprea. The network helps show where Corina Oprea may publish in the future.

Co-authorship network of co-authors of Corina Oprea

This figure shows the co-authorship network connecting the top 25 collaborators of Corina Oprea. A scholar is included among the top collaborators of Corina Oprea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Corina Oprea. Corina Oprea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients 2025 ·Blood ·Enrique M. Ocio, Aurore Perrot, Jesús F. San Miguel, Lionel Karlin, Joaquín Martínez‐López, (unknown), Paula Rodríguez‐Otero, Mohamad Mohty, (unknown), Meletios Α. Dimopoulos, Xavier Leleu, María‐Victoria Mateos, Philippe Moreau, Sandrine Macé, Ercem Kodas, Christina Tekle, (unknown), Corina Oprea, Thierry Façon	0
2	805MO Real-world efficacy and safety of tisagenlecleucel (CTL019) for relapse or refractory follicular lymphoma patients included in the early access program through the French DESCAR-T registry 2024 ·Annals of Oncology ·Emmanuel Bachy, Catherine Thiéblemont, Roch Houot, (unknown), Guillaume Cartron, Gabriel Brisou, Olivier Casasnovas, (unknown), Franck Morschhauser, Fabrice Jardin, Loïc Ysebaert, (unknown), (unknown), (unknown), (unknown), Corina Oprea	1
3	30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis 2024 ·HemaSphere ·Enrique M. Ocio, Aurore Perrot, Philippe Moreau, María‐Victoria Mateos, Sara Bringhen, Joaquín Martínez‐López, Lionel Karlin, (unknown), Corina Oprea, Yi Li, Ercem Kodas, Jesús F. San Miguel	3
4	The Effects of Impartiality Disclosure on Brand Objectives for No and Multiple Product Endorsements 2023 ·Corina Oprea	1
5	30-Minute Infusion of Isatuximab in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Results of a Phase 1b Study 2023 ·Blood ·Enrique M. Ocio, Aurore Perrot, Philippe Moreau, María‐Victoria Mateos, Sara Bringhen, Joaquín Martínez‐López, Lionel Karlin, Igor Wolfgang Blau, (unknown), Maurizio Martelli, Corina Oprea, (unknown), Ercem Kodas, Jesús F. San Miguel	1
6	A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma 2020 ·Leukemia ·Joseph Mıkhael, Joshua Richter, Ravi Vij, Craig E. Cole, Jeffrey A. Zonder, Jonathan L. Kaufman, William Bensinger, Meletios Α. Dimopoulos, Nikoletta Lendvai, Parameswaran Hari, Enrique M. Ocio, Cristina Gasparetto, Shaji Kumar, Corina Oprea, Marielle Chiron, (unknown), Éric Charpentier, Jesús F. San Miguel, Thomas G. Martin	37
7	Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). 2018 ·Journal of Clinical Oncology ·Robert Z. Orlowski, Hartmut Goldschmidt, Michèle Cavo, Thomas G. Martin, Gautier Paux, Corina Oprea, Thierry Façon	21
8	A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation 2017 ·Blood ·Enrique M. Ocio, Sara Bringhen, Stefania Oliva, Paula Rodríguez‐Otero, (unknown), Corina Oprea, Vivian Wei, (unknown), Joaquín Martínez‐López	8
9	A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia 2015 ·Clinical Lymphoma Myeloma & Leukemia ·Hagop M. Kantarjian, Bruno Lioure, Stella K. Kim, Ehab Atallah, Thibaut Leguay, (unknown), (unknown), Martine Escoffre‐Barbe, Xavier Thomas, Jörge E. Cortes, Elias Jabbour, Susan O’Brien, Pierre Bories, Corina Oprea, Laurence Hatteville, Hervé Dombret	52
10	Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors 2014 ·Investigational New Drugs ·Rastislav Bahleda, Cristiana Sessa, Gianluca Del Conte, Luca Gianni, Giuseppe Capri, Andréa Varga, Corina Oprea, (unknown), (unknown), Jean‐Charles Soria	20
11	A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors 2014 ·Anti-Cancer Drugs ·(unknown), Dorothée Sémiond, (unknown), (unknown), (unknown), Ger‐Jan Sanderink, Corina Oprea, (unknown), Sally Clive	13
12	A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours 2014 ·British Journal of Cancer ·Ferry A.L.M. Eskens, Patricia Tresca, Diégo Tosi, Leni van Doorn, (unknown), Ate van der Gaast, Christine Veyrat‐Follet, Corina Oprea, (unknown), Véronique Dièras	30
13	Abstract 749: A Phase I, open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors 2012 ·Cancer Research ·(unknown), Dorothée Sémiond, (unknown), Hélène Fontaine, (unknown), Gérard Sanderink, Corina Oprea, Sally Clive	2
14	Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer 2011 ·Oncology ·Thomas Bachelot, Agathe Bajard, Isabelle Ray‐Coquard, (unknown), David Coeffic, (unknown), Martial Boisseau, (unknown), (unknown), Corina Oprea, (unknown), Jean‐Paul Guastalla, David Pérol	12
15	Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors. 2010 ·Journal of Clinical Oncology ·Patricia Tresca, Diégo Tosi, Leni van Doorn, Hélène Fontaine, Ate van der Gaast, Christine Veyrat‐Follet, Corina Oprea, V. Diéras, (unknown)	5
16	A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma. 2010 ·Journal of Clinical Oncology ·(unknown), Catherine Thiéblemont, Fabrice Jardin, (unknown), M. Meignan, José Cabeçadas, Philippe Gaulard, H Tilly, Corina Oprea, Corinne Haïoun	5
17	Phase II Trial of Docetaxel Therapy in Patients with Advanced Hepatocellular Carcinoma 2006 ·Oncology ·Mohamed Hebbar, Olivier Ernst, Stéphane Cattan, Sophie Dominguez, Corina Oprea, Philippe Mathurin, Jean–Pierre Triboulet, J Paris, François‐René Pruvot	28
18	Primary diffuse large B‐cell non‐Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases 2005 ·British Journal of Haematology ·Corina Oprea, Călin Cainap, R. Azoulay, (unknown), Elias Jabbour, Serge Koscielny, Simona Lapusan, D. Vanel, J. Bosq, Vincent Ribrag	25
19	Troubles neurologiques isolés révélant une maladie de Biermer chez le sujet jeune 2001 ·La Revue de Médecine Interne ·Emmanuel Andrès, (unknown), Fernando Augusto Batista Campos, Corina Oprea, (unknown), J Warter, P. Dufour, F. Maloisel	13
20	Y a-t-il une place pour l'interféron-α dans la stratégie thérapeutique de la maladie de Castleman multicentrique? 2000 ·La Revue de Médecine Interne ·F. Maloisel, Emmanuel Andrès, Fernando Augusto Batista Campos, Corina Oprea, Marion Deslandres, (unknown), Jean‐Emmanuel Kurtz, (unknown), P. Dufour	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact